安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Agios
Since our founding, Agios has been a pioneering leader in cellular metabolism, advancing therapies for patients with unmet needs Our mature and unique understanding of the science is foundational to our success and the connective thread that binds our people and our pipeline together
- Pipeline - Agios
Agios has a proven track record of leveraging our expertise in cellular metabolism to develop new therapies and bring innovative medicines to patients in need Building on our core capabilities, we are advancing a robust pipeline focused on rare diseases
- Leadership - Agios
At Agios, leadership means building stronger bonds with colleagues, partners and patient communities and honoring each of their perspectives to make the process of developing life-changing treatments for patients with rare diseases more collaborative, creative and productive
- About Us - Agios
At Agios, building bonds and cultivating relationships are at the heart of our ability to create life-changing therapies for people with rare diseases We are a biopharmaceutical company that believes connections unlock potential
- Investors Overview – Agios Pharmaceuticals, Inc.
The Investor Relations website contains information about Agios Pharmaceuticals, Inc 's business for stockholders, potential investors, and financial analysts
- History - Agios
For nearly 15 years, Agios has been committed to furthering the science of cellular metabolism to identify therapies for patients with unmet needs Our deep and differentiated understanding of the science is foundational to our success and the connective thread that binds our people and our pipeline together
- Our Science - Agios
Agios is the pioneer in the science of pyruvate kinase (PK) activation PK is an enzyme that plays an important role in regulating cell metabolism It is responsible for the final step in glycolysis in red blood cells, which is required for maintaining red blood cell energy levels and structure
- Agios EHA 2025 Data Room – Agios
Agios is presenting new data on mitapivat and tebapivat, the company’s two pyruvate kinase (PK) activators, at EHA 2025 Select presentations and publications at EHA 2025 will include: An oral presentation of results from the ACTIVATE-KidsT Phase 3 study of mitapivat in children aged 1 to ; 18 years with PK deficiency who are regularly
|
|
|